Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biocorrx Inc
(OP:
BICX
)
0.3000
UNCHANGED
Streaming Delayed Price
Updated: 3:54 PM EDT, Oct 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
10
Open
0.3000
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.3000
Today's Range
0.3000 - 0.3000
52wk Range
0.2820 - 1.580
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
BioCorRx Reports Business Update for the Second Quarter of 2024
August 15, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Intellectual Property
Exposures
Intellectual Property
BioCorRx Reports Business Update for the First Quarter of 2024
May 16, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Death
Intellectual Property
Exposures
Death
Intellectual Property
Performance
YTD
-58.62%
-58.62%
1 Month
N/A
N/A
3 Month
-36.17%
-36.17%
6 Month
-60.00%
-60.00%
1 Year
-81.01%
-81.01%
More News
Read More
BioCorRx Reports Business Update for the First Quarter of 2024
May 16, 2024
Via
TheNewswire.com
Topics
Death
Intellectual Property
Exposures
Death
Intellectual Property
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
April 03, 2024
Via
NewMediaWire
Topics
Intellectual Property
Exposures
Intellectual Property
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
April 03, 2024
Via
TheNewswire.com
Topics
Intellectual Property
Exposures
Intellectual Property
BioCorRx Reports Business Update for 2023
April 02, 2024
Via
NewMediaWire
Topics
Death
Exposures
Death
BioCorRx Reports Business Update for 2023
April 02, 2024
Via
TheNewswire.com
Topics
Death
Exposures
Death
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
February 28, 2024
Via
NewMediaWire
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
February 28, 2024
Via
TheNewswire.com
Topics
Death
Exposures
Death
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
February 08, 2024
Via
NewMediaWire
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
February 08, 2024
Via
TheNewswire.com
Collective Audience And 3 Other Stocks Under $1 Insiders Are Buying
January 18, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President
January 09, 2024
Via
NewMediaWire
BioCorRx Reports Business Update for the Third Quarter of 2023
November 14, 2023
Via
NewMediaWire
Topics
Death
Exposures
Death
BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder
August 15, 2023
Via
NewMediaWire
Exposures
Product Safety
BioCorRx Reports Business Update for the Second Quarter of 2023
August 14, 2023
Via
NewMediaWire
Exposures
Product Safety
BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder
July 18, 2023
Via
NewMediaWire
Topics
Death
Exposures
Death
Product Safety
Rezolute And 2 Other Penny Stocks Insiders Are Aggressively Buying
July 07, 2023
Via
Benzinga
BioCorRx Provides Business Update for the First Quarter of 2023
May 16, 2023
Via
NewMediaWire
BioCorRx Provides Business Update for 2022
April 03, 2023
Via
NewMediaWire
BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting
March 07, 2023
Via
NewMediaWire
BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data
February 23, 2023
Via
NewMediaWire
Exposures
Product Safety
BioCorRx to Present at Sequire Biotechnology Conference on February 2nd
January 27, 2023
Via
NewMediaWire
BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of Directors
January 24, 2023
Via
NewMediaWire
BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
January 19, 2023
Via
NewMediaWire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
